Effect of Fish Oil on Athlete's Executive Function
NCT04570995, Not applicable, Terminated, Wake Forest University Health Sciences
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of Fish Oil on Athlete's Executive Function | ClinicalTrials.gov |
| NCT number | NCT04570995 | ClinicalTrials.gov |
| Status | Terminated | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 22 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Wake Forest University Health Sciences | ClinicalTrials.gov |
| Conditions | Brain Health, Brain Function, Brain Development | ClinicalTrials.gov |
| Interventions | Fish Oil, Safflower Oil | ClinicalTrials.gov |
| First posted | 2020-09-30 | ClinicalTrials.gov |
| Last updated | 2023-03-22 | ClinicalTrials.gov |
Registered outcomes 39
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Barkley Deficits in Executive Functioning Scale (BDEFS) | visit #2 (~6-8 weeks after baseline) | Evaluate dimensions of adult executive functioning in daily life - self administered - Items are answered on a 4-point scale ranging from "1= Never or rarely" to " 4 = Very often"; α's range from 0.91 to 0.96. Higher scores are interpreted as indicating greater deficits in EF - The Barkley Deficits in Executive Functioning Scale is an 89 item self-report measure of executive functioning. | ClinicalTrials.gov |
| Primary | Stroop Test | visit #2 (~6-8 weeks after baseline) | Subjects will be asked to read words of colors, state the colors of various letters to test processing speed, and state the color of the font of a word when the actual word describes a conflicting color to test response inhibition (executive functioning). Three scores, as well as an interference score, are generated using the number of items completed on each page, with higher scores reflecting better performance and less interference on reading ability. T-Scores of 40 or less are considered "low." Word, color, and color-word T-Scores above 40 or are considered "normal". | ClinicalTrials.gov |
| Primary | Stroop Test | Baseline, Day 1 | Subjects will be asked to read words of colors, state the colors of various letters to test processing speed, and state the color of the font of a word when the actual word describes a conflicting color to test response inhibition (executive functioning). Three scores, as well as an interference score, are generated using the number of items completed on each page, with higher scores reflecting better performance and less interference on reading ability. T-Scores of 40 or less are considered "low." Word, color, and color-word T-Scores above 40 or are considered "normal". | ClinicalTrials.gov |
| Primary | Trail Making Test | visit #2 (~6-8 weeks after baseline) | Visual attention, task switching - self administered - The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test results are reported as the time that took to complete. Longer times denotes worse outcomes. | ClinicalTrials.gov |
| Primary | Trail Making Test | Baseline, Day 1 | Visual attention, task switching - self administered - The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test results are reported as the time that took to complete. Longer times denotes worse outcomes. | ClinicalTrials.gov |
| Primary | Stop-Signal Test | visit #2 (~6-8 weeks after baseline) | Response inhibition - self administered - stop signal task is a test of inhibition of prepotent responses. It requires the participant to respond as quickly as possible to a predetermined stimulus, the go trial, but to abort any response when a subsequently presented stop signal is displayed. Speed and accuracy on the go trials are measured. The stop signal reaction time is calculated and reported | ClinicalTrials.gov |
| Primary | Stop-Signal Test | Baseline, Day 1 | Response inhibition - self administered - stop signal task is a test of inhibition of prepotent responses. It requires the participant to respond as quickly as possible to a predetermined stimulus, the go trial, but to abort any response when a subsequently presented stop signal is displayed. Speed and accuracy on the go trials are measured. The stop signal reaction time is calculated and reported | ClinicalTrials.gov |
| Primary | Digit Span | visit #2 (~6-8 weeks after baseline) | Working memory - self administered -Digit Span measures verbal short-term memory, defined as the system that allows for temporary storage of information, and is crucial in everyday tasks such as remembering a telephone number or understanding long sentences - The average digit span for normal adults without error is seven plus or minus two. The Digit Span test is a measure of verbal short-term/working memory. Scores range from 0 to 28, with higher scores indicating better verbal short-term/working memory. | ClinicalTrials.gov |
| Primary | Digit Span | Baseline, Day 1 | Working memory - self administered -Digit Span measures verbal short-term memory, defined as the system that allows for temporary storage of information, and is crucial in everyday tasks such as remembering a telephone number or understanding long sentences - The average digit span for normal adults without error is seven plus or minus two. The Digit Span test is a measure of verbal short-term/working memory. Scores range from 0 to 28, with higher scores indicating better verbal short-term/working memory. | ClinicalTrials.gov |
| Primary | Wisconsin Card Sort Test | visit #2 (~6-8 weeks after baseline) | Will be administered to assess preservation and abstract thinking. The The task measures how well people can adapt to the changing rules, and their cognitive flexibility. The number of perseverative errors in Wisconsin Card Sorting Task is the most robust variable of the task to assess cognitive flexibility. Higher scores show an impairment of cognitive flexibility. | ClinicalTrials.gov |
| Primary | Wisconsin Card Sort Test | Baseline, Day 1 | Will be administered to assess preservation and abstract thinking. The The task measures how well people can adapt to the changing rules, and their cognitive flexibility. The number of perseverative errors in Wisconsin Card Sorting Task is the most robust variable of the task to assess cognitive flexibility. Higher scores show an impairment of cognitive flexibility. | ClinicalTrials.gov |
| Primary | Circulating levels of fatty acids - EPA (eicosapentaenoic acid) in plasma | visit #2 (~6-8 weeks after baseline) | centrifuged to isolate plasma for EPA fatty acid analysis | ClinicalTrials.gov |
| Primary | Circulating levels of fatty acids - EPA on red blood cells | visit #2 (~6-8 weeks after baseline) | centrifuged to isolate red blood cells for EPA fatty acid analysis | ClinicalTrials.gov |
| Primary | Circulating levels of fatty acids - DHA (docosahexaenoic acid) on Red blood cells | visit #2 (~6-8 weeks after baseline) | centrifuged to isolate red blood cells for DHA fatty acid analysis | ClinicalTrials.gov |
| Primary | Circulating levels of fatty acids - DHA in plasma | visit #2 (~6-8 weeks after baseline) | centrifuged to isolate plasma for DHA fatty acid analysis | ClinicalTrials.gov |
| Secondary | Capsule consumption compliance | Visits 2 (Week~6-8 weeks after baseline ) and visit 5 (up to 9 months) | Percentage capsules taken | ClinicalTrials.gov |
| Secondary | Weight | Visits 1 to 5, from baseline up to 9 months | ClinicalTrials.gov | |
| Secondary | BMI | Visits 1 to 5, from baseline up to 9 months | ClinicalTrials.gov | |
| Secondary | Waist circumference | Visits 1 to 5, from baseline up to 9 months | ClinicalTrials.gov | |
| Secondary | Hip circumferences | Visits 1 to 5, from baseline up to 9 months | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Card Sorting Test (Berg) | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Stop-Signal Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Task Switching Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)